Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News CytomX Therapeutics Inc CTMX

Healthcare Biotechnology
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:CTMX)

CytomX Therapeutics to Present at Upcoming December Investor Conferences

GlobeNewswire November 25, 2025

CytomX Therapeutics to Present at the Jefferies London Healthcare Conference

GlobeNewswire November 13, 2025

CytomX Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire November 6, 2025

CytomX Therapeutics to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

GlobeNewswire November 4, 2025

CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025

GlobeNewswire October 30, 2025

CytomX Therapeutics Appoints Rachael Lester as Chief Business Officer

GlobeNewswire October 20, 2025

CytomX Therapeutics to Present at Upcoming September Investor Conferences

GlobeNewswire August 28, 2025

CytomX Therapeutics Provides Update on CX-2051 Phase 1 Study

GlobeNewswire August 13, 2025

CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire August 7, 2025
View More News ››

Opinion & Analysis (NDAQ:CTMX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:CTMX)

Buy buddy buy because it's taking off this morning.

Otherwise you guys out there will be left behind by this stock today
coolfooldumbguy - May 12, 2025

The report

So. Nothing tilt he end of the year, then nothign til t eend of next year.  Hmmph.
zalmonella - May 9, 2024

CTMX..... Early a.m runner

On watch  Going Skiing...no position  Cheers !
Iseneschal - January 6, 2023

From boom to boot

Nice rise throughoutthe week, adn then last trad of the day on the 1st for 780,00 shars at whatever the market would get for it...
zalmonella - February 2, 2022

EMERGING PARADIGMS IN TREATMENT OF MELANOMA!

$CTMX $NKTR $MGNX $IDYA $ALKS Melanoma, a form of skin cancer, accounts for about 1% of skin cancers but is responsible for over 7...
AviseAnalytics - January 26, 2022
View more Bullboard ››

Oregen Energy Corp

Oregen Energy Corp

Oregen Energy Corp., an energy and resource exploration company, focuses on acquiring and advancing natural resources ...
View More »